Legumain (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Legumain (LGMN; UniProt Q99538) produced in HEK293 cells. Suited for asparaginyl endopeptidase activity assays, inhibitor IC50 profiling, and antibody validation in lysosomal protease research.
Expression system
HEK293
Cat. #
REC-Legumain

In stock

SKU
REC-Legumain
$498.00

Target Overview

Legumain (UniProt Q99538; gene LGMN) is a lysosomal cysteine protease classified as EC 3.4.22.34. The full-length human precursor spans 433 amino acids and undergoes autocatalytic processing to yield the mature active enzyme. Legumain exhibits strict specificity for hydrolysis of asparaginyl bonds, with secondary, slower activity against aspartyl bonds that is enhanced under acidic conditions — properties that make pH-controlled activity assays a standard characterisation tool. This recombinant form is expressed in HEK293 mammalian cells, providing eukaryotic post-translational processing, including glycosylation patterns relevant to the native lysosomal environment. Researchers use this reagent in fluorogenic substrate cleavage assays (e.g., Ac-AAVNL-AFC or Z-Asn-NHMec peptide substrates) to measure specific activity and determine kinetic parameters (Km, kcat). It is also widely used in small-molecule inhibitor screening and IC50 determination, where the mammalian expression system is preferred over bacterial material to avoid misfolding artefacts. The defined, single-species preparation is suitable as a positive control antigen for Western blot and IHC antibody validation experiments; researchers using this recombinant for that purpose can pair it with the Triple Point Biologics matched anti-Legumain antibody (SKU: RP-Legumain). Additional uses include mass spectrometry-based substrate identification and protein–protein interaction studies probing Legumain's role in antigen presentation and lysosomal protein turnover. Validated reactivity is confirmed for human; cross-reactivity with mouse, rat, non-human primate, and dog samples is predicted based on sequence conservation.

Background

Legumain (LGMN; EC 3.4.22.34) is the only known mammalian member of the C13 family of cysteine proteases and resides primarily in the lysosomal/endosomal compartment. Its strict preference for hydrolysis at asparagine residues — and, at lower pH, at aspartate residues — distinguishes it mechanistically from the broader cathepsin family and makes it a tractable biochemical target for selective small-molecule tool compound development. In basic immunology research, Legumain has been characterised as a processing enzyme within the MHC class II antigen presentation pathway, where it acts on lysosomal protein substrates to generate peptide epitopes. Published work has also implicated the enzyme in cross-presentation through maturation of Perforin-2 (MPEG1) in dendritic cells, contributing to antigen translocation to the cytosol. Both activities position this recombinant as a useful reagent for in vitro reconstitution of antigen processing steps. More recent published studies have expanded the research context substantially. Xia Y et al. (2026, PMID 42051490) investigated LGMN in macrophage–fibroblast crosstalk in pulmonary fibrosis models, identifying it as a candidate research target in fibrotic signalling. Liu M et al. (2026, PMID 41933939) reported that Legumain restrains granuloma formation by modulating mTORC1/STAT1-dependent M1 macrophage polarisation in sarcoidosis, a finding that underscores the enzyme's role in inflammatory macrophage biology and that was supported by in vitro enzymatic inhibition experiments of the type this recombinant enables. In neurological research, Legumain has been studied in the context of microglial activation (Heiss CN et al., 2026, PMID 41695273) and has been identified in Mendelian randomisation analyses as a genetically supported candidate research target for Alzheimer's disease (Zhao YH et al., 2026, PMID 41630303). Legumain has also appeared in proteomics-based biomarker discovery studies, including cervicovaginal fluid profiling for endometriosis (Paterson ESJ et al., 2026, PMID 41906395), illustrating its detection as an abundant lysosomal enzyme in secreted and shed proteomes. Across these published experimental contexts, the recombinant protein serves as an activity reference, an inhibitor-screen positive control, and an antigen standard — roles that require a well-characterised, mammalian-expressed preparation with confirmed specific activity.

Applications

  • Fluorogenic substrate cleavage activity assay (e.g., Ac-AAVNL-AFC or Z-Asn-NHMec) to determine Km and kcat
  • Small-molecule inhibitor IC50 determination by continuous fluorescence activity assay
  • Positive control antigen for Western blot validation of anti-Legumain antibodies
  • Positive control antigen for IHC antibody titration and specificity confirmation
  • In vitro reconstitution of lysosomal antigen processing steps for MHC class II presentation studies
  • Mass spectrometry-based substrate identification and cleavage site mapping
  • Macrophage polarisation and inflammatory signalling assays requiring recombinant enzyme supplementation
  • Enzyme-linked immunosorbent assay (ELISA) standard curve calibration for Legumain quantification in biological samples

References

  1. Xia Y et al. LGMN promotes crosstalk between macrophages and fibroblasts in pulmonary fibrosis: a potential therapeutic target. Front Immunol. 2026. doi:10.3389/fimmu.2026.1789907. PMID: 42051490.
  2. Liu M et al. Legumain Restrains Granuloma Formation by Inhibiting mTORC1/STAT1-Mediated M1 Macrophage Polarization in Sarcoidosis. Adv Sci (Weinh). 2026. doi:10.1002/advs.202520635. PMID: 41933939.
  3. Paterson ESJ et al. Proteomic Analysis of Cervicovaginal Fluid for Diagnostic Endometriosis Biomarker Discovery. Proteomics Clin Appl. 2026. doi:10.1002/prca.70044. PMID: 41906395.
  4. Heiss CN et al. The temporal and stimuli-specific effects of LPS and IFNγ on microglial activation. Front Aging Neurosci. 2026. doi:10.3389/fnagi.2026.1756410. PMID: 41695273.
  5. Zhao YH et al. Identification of potential drug targets for Alzheimer's disease from genetic insights: A Mendelian randomization study. Medicine (Baltimore). 2026. doi:10.1097/MD.0000000000045715. PMID: 41630303.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight does recombinant human Legumain run at on SDS-PAGE?

The full-length human Legumain precursor (433 aa, UniProt Q99538) has a predicted molecular weight of ~49 kDa, but the protein undergoes autocatalytic N- and C-terminal trimming to yield the mature active form, which migrates at approximately 36–40 kDa under denaturing conditions. Because this recombinant is expressed in HEK293 cells, N-linked glycosylation adds apparent mass, so the observed band on SDS-PAGE typically runs between 40–47 kDa. Expect diffuse banding if the glycosylation is heterogeneous — this is normal for the native lysosomal form and does not indicate degradation.

What processing forms of Legumain are present in the recombinant preparation and how do they differ?

Legumain is synthesized as a ~56 kDa zymogen (pro-Legumain) that undergoes stepwise autocatalytic processing. The C-terminal prodomain is removed first under mildly acidic conditions, generating an intermediate, followed by N-terminal cleavage to produce the fully mature ~36–40 kDa active enzyme. This recombinant preparation is provided predominantly as the processed, active form. A minor pro-form band at ~49–56 kDa may be visible on SDS-PAGE under reducing conditions. The active site cysteine (Cys189) requires a reducing environment; include 1–5 mM DTT in your assay buffer to maintain full activity.

What substrate should I use for a Legumain fluorogenic activity assay?

The most commonly used fluorogenic substrates for Legumain are Z-Ala-Ala-Asn-NHMec (Z-AAN-NHMec) and Ac-AAVNL-AFC, both of which exploit Legumain's strict asparaginyl-bond specificity. Z-AAN-NHMec (Ex 360 nm / Em 460 nm) is widely preferred for its low background. Use substrate concentrations bracketing the Km (~50–200 µM) for Michaelis-Menten kinetics. Run assays at pH 5.0–5.5 in 50 mM sodium acetate, 1 mM EDTA, 5 mM DTT, 37 °C — the acidic pH is critical for optimal activity and mirrors the lysosomal environment where Legumain is naturally active.

What buffer conditions maximize Legumain enzymatic activity in vitro?

Legumain is a lysosomal protease with a pH optimum between 5.0 and 5.5. For activity assays, use 50 mM sodium acetate pH 5.0, 1 mM EDTA, 5 mM DTT, 0.01% Tween-20. The EDTA chelates trace metal ions that can inhibit the active-site cysteine, and DTT maintains the cysteine in its reduced state. Note that the storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) is deliberately neutral to retard autocatalytic activity during storage — transfer to assay buffer and pre-incubate at 37 °C for 10 minutes before adding substrate to allow full activation.

What starting enzyme concentration should I use for Legumain IC50 inhibitor screening?

For IC50 determination, titrate Legumain in the range of 0.5–5 nM final concentration in your assay well, using Z-AAN-NHMec substrate at or near its Km (~100 µM). At these concentrations, less than 10% substrate conversion should occur at the assay endpoint (typically 30–60 min), which is required for accurate IC50 measurement by the Morrison equation if your inhibitors are tight-binders. Use a 384-well plate format if throughput is a priority. Include E-64 (a pan-cysteine protease inhibitor) as a positive inhibition control to verify enzyme activity in each run.

Can I use recombinant Legumain as a Western blot positive control with the RP-Legumain antibody?

Yes — this recombinant is specifically validated as a positive control for the matched rabbit polyclonal antibody RP-Legumain (/anti-legumain-rabbit-polyclonal-antibody), which was generated from the same expression system. Load 20–50 ng of recombinant Legumain per lane alongside your cell lysate samples. Expect a primary band at 40–47 kDa (mature glycosylated form) and potentially a fainter pro-form band at ~49–56 kDa depending on preparation lot. Using the recombinant and the matched antibody together provides an unambiguous, lot-consistent reference band for antibody validation experiments.

How much recombinant Legumain should I load for Western blot positive control compared to cell lysate?

Load 20–50 ng of recombinant Legumain per lane for a robust signal with RP-Legumain at 1:1,000–1:2,000 primary antibody dilution. This is typically well below the total protein loaded in a cell lysate lane (10–30 µg), so run the recombinant in a dedicated lane rather than mixing it into lysate. Endogenous Legumain expression is highest in kidney, placenta, and monocyte-derived cells — if your cell line expresses low Legumain, the recombinant lane provides a reliable anchor for band identification. Reduce to 10 ng if background is high; increase to 100 ng if using a shorter ECL exposure.

How should I handle and store recombinant Legumain to preserve activity after thawing?

Recombinant Legumain is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol as single-use aliquots. Store at -20 °C; do not subject to repeated freeze-thaw cycles, as each cycle can result in significant activity loss for cysteine proteases. After thawing, keep on ice and use within the same working day. If you need to dilute for assay, prepare intermediate stocks in assay buffer (pH 5.0 acetate) containing 0.1% BSA as a carrier to prevent surface adsorption at low concentrations (<10 nM). Validated shelf life is 12 months from date of manufacture when stored correctly.

Validation imagery coming soon

Western blot validation figures for REC-Legumain will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →